close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medicenna Thera Corp (OP:MDNAF)

0.2626 -0.0124 (-4.51%)
Streaming Delayed Price Updated: 3:07 PM EDT, Jul 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Medicenna Thera Corp

News headline image
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
New U.S. patents extend protection for cellular immunotherapy applications, immune cell targeting constructs and bizaxofusp combination therapy with anti-VEGF agents for CNS tumors; global portfolio... 
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto... 
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics Announces Participation in Upcoming Conferences
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Announces Changes to Board Composition
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics Announces Participation in Upcoming Conferences
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Announces Results of Annual Meeting of Shareholders
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines
Granted patents provide broad composition, formulation, and method of use protection across key global markets including use of MDNA11 in combination with checkpoint inhibitors and a novel formulation... 
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream ↗
Via Stocktwits
News headline image
Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX
From OTC Markets
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today